Skip to content

Gastric volume measurement and risk assessment of aspiration by antrum ultrasonography in different administration methods before painless gastroscopic anesthesia

Gastric volume measurement and risk assessment of aspiration by antrum ultrasonography in different administration methods before painless gastroscopic anesthesia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056698
Enrollment
Unknown
Registered
2022-02-10
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk of aspiration before painless gastroscopic anesthesia

Interventions

control group:Control group: The control group was given dacronine gum slurry before examination, and the specific operations were as follows: 10 min before examination, 10 ml dacronine gum slurry was
experimental group:The control group was given streptaypsin granules on a basis. The method was as follows: 20-30 min before detection, dissolve 1 package of streptaypsin granules (Beijing Teide Pharm
control group:Electrical stimulation at Zusanli point was performed 30 minutes before surgery
experimental group:Electrical stimulation at Zusanli point was performed 30 minutes before surgery

Sponsors

Meiqin Zhai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing gastroscopy under general anesthesia; 2. Those aged over 18 and under 65; 3. ASA grade I to III; 4. The patient is conscious and understands the investigation content; 5. Those who have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. History of organic digestive system diseases (such as gastrointestinal bleeding, pyloric obstruction, upper gastrointestinal surgery history); 3. History of mental illness or incompatible author; 4. Patients with cardiac insufficiency, renal function damage and active liver disease; 5.BMI>35 kg/m2 6. Those who have a history of allergy to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
anteroposterior;craniocaudal;

Secondary

MeasureTime frame
Gastric juice attraction;PH of Gastric juice;

Countries

China

Contacts

Public ContactMeiqin Zhai

Shenzhen Hospital, Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong (Futian)

zmq7304@126.com+86 13928433543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026